ArticleNPJ breast cancer2025

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).

Laura M Spring et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.